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Abstract
Background: Open globe ocular trauma complicated by intraocular scarring (proliferative vitreoretinopathy) is a
relatively rare, blinding, but potentially treatable condition for which, at present, surgery is often unsatisfactory and
visual results frequently poor. To date, no pharmacological adjuncts to surgery have been proven to be effective.
The aim of the Adjunctive Steroid Combination in Ocular Trauma (ASCOT) randomised controlled trial is to
determine whether adjunctive steroid (triamcinolone acetonide), given at the time of surgery, can improve the
outcome of vitreoretinal surgery in patients with open globe ocular trauma. This article presents the statistical
analysis plan for the main publication as approved and signed off by the Trial Steering Committee prior to the first
data extraction for the Data Monitoring Committee meeting report.
Methods/design: ASCOT is a pragmatic, multi-centre, parallel-group, double-masked randomised controlled trial.
The aim of the study is to recruit from 20–25 centres in the United Kingdom and randomise 300 eyes (from 300
patients) into two treatment arms. Both groups will receive standard surgical treatment and care; the intervention
arm will additionally receive a pre-operative steroid combination (triamcinolone acetonide) into the vitreous cavity
consisting of 4 mg/0.1 ml and 40 mg/1 ml sub-Tenon’s. Participants will be followed for 6 months post-surgery. The
primary outcome is the proportion of patients achieving a clinically meaning improvement in visual acuity in the
study eye at 6 months after initial surgery, defined as a 10 letter score improvement in the ETDRS (the standard
scale to test visual acuity).
Trial registration: ISRCTN30012492. Registered on 5 September 2014.
EudraCT2014-002193-37. Registered on 5 September 2014.
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Background
Trauma is a major cause of visual impairment and blind-
ness worldwide; in particular, it is the most common cause
of unilateral blindness [1, 2]. Approximately 1.6 million
people across the globe became blind as a result of ocular
trauma, with up to 19 million living with unilateral blind-
ness or low vision [2]. Ocular injuries invariably affect the
posterior segment of the eye, and vitreoretinal surgery is
required to prevent visual loss. Recent published results
have shown that, although vitreoretinal surgical tech-
niques have improved, outcomes remain unsatisfactory,
mainly due to the development of the intraocular scarring
response proliferative vitreoretinopathy (PVR) [3–6]. PVR
is the main cause of recurrent retinal detachment and
visual loss in eyes with open globe trauma (OGT). Al-
though final retinal attachment may now be achieved,
multiple surgeries are often needed, and visual results
remain very poor [7, 8]. PVR is a difficult vitreoretinal
surgical challenge, and its management is costly in both
patient time and healthcare resources [8]. To date, no
pharmacological adjuncts to surgery have been proven
to be effective in treating OGT complicated by PVR.
Experimental work has suggested that steroid (triam-
cinolone acetonide) treatment can reduce the severity
of PVR [9] and that it appears to have no significant
retinal toxicity [10].
Objective
The primary objective of the Adjunctive Steroid Com-
bination in Ocular Trauma (ASCOT) trial is to deter-
mine whether adjunctive triamcinolone acetonide, given
at the time of surgery, can improve visual acuity (VA) at
6 months compared with treatment as usual in eyes of
patients undergoing vitreoretinal surgery for OGT. Add-
itionally, the influence of the intervention on the develop-
ment of scarring (PVR), as well as the incidence of retinal
detachment, intraocular pressure (IOP) abnormalities and
other complications in eyes undergoing surgery for OGT,
will be examined. Quality of life measured using the
25-item Visual Function Questionnaire (VFQ-25) will
also be assessed.
Methods/design
ASCOT is a pragmatic, multi-centre, double-masked
randomised controlled trial. Three hundred adult partic-
ipants with OGT will be recruited from 20–25 centres
across the United Kingdom. The inclusion and exclusion
criteria are listed below.
Inclusion criteria
1. Adult subjects aged 18 years or older at the time
of enrolment
2. Full-thickness OGT undergoing vitrectomy
3. Ability to give written informed consent
4. Willingness to accept randomisation and attend
follow-up for 6 months
Exclusion criteria
1. Pre-existing uncontrolled uveitis
2. Definitive diagnosis of previous steroid-induced
glaucoma
3. Pregnant or breastfeeding females
4. Allergy or previous known adverse reaction to
triamcinolone acetonide
5. Current or planned systemic corticosteroid use
at a dose above physiological levels (e.g., >10 mg
prednisolone)
Participants will be individually randomised in a 1:1 ra-
tio to surgery plus adjunctive triamcinolone acetonide or
surgery only. Randomisation will be carried out by per-
muted blocks with stratification by trial centre conducted
using a telephone service to the Emergency Scientific
Medical Services global service hosted at the King’s
Clinical Trials Unit (KCTU) at King’s College London.
Randomisation and subsequent treatment allocation will
be performed intraoperatively once the operating surgeon
has confirmed that the retina is attached. The participants
in the intervention arm will receive pre-operative steroid
combination (triamcinolone acetonide) into the vitreous
cavity of the study eye, consisting of 4 mg/0.1 ml and 40
mg/1 ml sub-Tenon’s; the standard treatment group will
receive standard care only (surgery without adjunctive
treatment). The study eye is defined as the eye which
requires vitrectomy. It is extremely rare for patients to
experience bilateral OGT requiring surgery in both eyes;
however, for these cases, the surgeon will select the worse
eye (i.e., the eye with the least good potential visual out-
come, based on the pre-operative assessment of ocular
and, in particular, macular trauma) to be the study eye.
Patients will be followed and assessed at 3 months and 6
months post-surgery, in line with the usual clinical follow-
up appointments. Operating surgeons will be masked until
the end of surgery (when the adjunct is given); patients
and study investigators will be masked throughout, except
for one of the trial statisticians, who will be masked to
sub-group and will undertake analyses for reports to the
data monitoring committees. Ethics approval was granted
by the Central London NHS Research Ethics Committee.
All patients are to provide written informed consent prior
to randomisation.
Outcomes
Primary outcome
The primary outcome is defined as the proportion of
patients with a clinically meaningful improvement in VA
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in the study eye (yes or no). A meaningful improvement
in VA is defined as having an improvement in VA of 10
letters or more in the study eye and is calculated as the
difference between ETDRS score (Early Treatment Dia-
betic Retinopathy Study, the standard scale to test VA,
which is based on letters of decreasing size on a chart)
measured at baseline and 6-month follow-up [11]. The
ETDRS score is measured by using the ETDRS vision
chart at a starting distance of 4 m. The patient starts
from the top of the chart and reads down the chart,
and the score is the sum of the number of letters that
could be correctly identified. The ETDRS score will be
dichotomised into two groups: patients with a change
in VA <10 and patients with a meaningful improvement
in VA (change in VA ≥10 letters).
The primary outcome was chosen to be analysed as a
binary variable instead of a continuous one for the follow-
ing reasons: (1) the binary outcome represents a clinically
more meaningful and tangible result for patients and clini-
cians that can be easily communicated, and (2) the results
of the ASCOT pilot study demonstrated a non-identical
distributional shift in ETDRS letter score at follow-up
between the two treatment arms. This resulted in a small
mean difference in ETDRS scores between treatment arms
potentially masking a clinically important difference in the
proportion of participants with a meaningful improve-
ment in VA between treatment arms.
Secondary outcomes
The secondary outcomes are described below:
1. ETDRS letter score as measured by ETDRS vision
charts at 6-month follow-up (analysed as a
continuous outcome)
2. The proportion of patients in whom retinal
detachment with PVR occurs at any time point
within 6 months of the study vitrectomy
3. The proportion of patients in whom stable,
complete retinal reattachment (without internal
tamponade present) is achieved at 6 months after
study vitrectomy
4. The proportion of patients in whom stable macular
retinal reattachment (without internal tamponade
present) is achieved at 6 months after study
vitrectomy
5. The proportion of patients in whom a tractional
retinal detachment occurs at any time point within
6 months of the study vitrectomy
6. The number of operations needed to achieve stable
retinal reattachment (either complete or macular)
at 6 months after the study vitrectomy
7. The proportion of patients with hypotony
(<6 mmHg) at any time point within 6 months
of the study vitrectomy
8. The proportion of patients with raised IOP
(>25 mmHg) at any time point within 6 months
of the study vitrectomy
9. The proportion of patients who develop macular
pucker by 3 and 6 months and/or require macular
pucker surgery at any time point within 6 months of
the study vitrectomy
10.Quality of life at 6 months after the study
vitrectomy based on the following:
(a)Client Service Receipt Inventory (CSRI)
(b)EQ-5D-5L questionnaire
(c)VFQ-25
Detailed analysis plans for these health economic as-
sessments are documented separately by the trial’s health
economist. Note that all eye-related outcomes relate to
the study eye.
Sample size calculation
With 90 % power and 5 % significance (two-sided test), a
sample size of 140 per group will be required to detect a
19 % increase (from 55 % to 74 %) in the proportion of
participants with a minimum improvement in VA of ≥10
EDTRS letter score. The target sample size has been in-
flated to 300 to allow for a 7 % dropout rate.
Statistical analyses
Trial profile
The flow of participants will be displayed in a Consolidated
Standards of Reporting Trials (CONSORT) diagram, as
shown in Fig. 1. The number of protocol deviations with
reasons will be reported.
Data management and quality assurance
Study data will be initially recorded on worksheets and
then entered, by designated research personnel in each
study centre, into an online database (InferMed MACRO;
Elsevier, London, UK) hosted at the KCTU at King’s Col-
lege London. Research coordinators at each site and the
trial manager will periodically perform basic checks, such
as examining for improbable values and data complete-
ness. Errors will be explored and checked with original
source data. After the last patient is followed, all queries
resolved and all data fields completed with data or missing
data codes, the database will be locked for final analysis,
and this process will be overseen by KCTU.
General analysis principles
The analytical principles outlined will be followed as
closely as possible in the analysis and reporting of trial
data. The statistical analysis plan is not intended to restrict
exploratory or other sensible and standard reporting prac-
tices. There are no plans for any formal comparisons
between treatment arms until final database lock. Analysis
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will be undertaken by the trial statistician, who is
masked to sub-groups. Group allocation will be re-
vealed to the study team after the study analytical
report has been constructed.
Missing outcome data are anticipated to be low, and
the sample size includes provision for withdrawal and
loss to follow-up. The main analyses for the primary and
secondary outcomes will follow the intention-to-treat
principle: All randomised participants with primary out-
come data will be analysed in their assigned treatment
groups, regardless of the treatment they actually re-
ceived. A sensitivity analysis examining assumptions
regarding missing outcome data will be undertaken. (See
below for a discussion on missing data.) As the interven-
tion occurs immediately after randomisation, the safety
population will consist of all randomised participants
unless it is documented that they did not receive the
intervention. All statistical tests and confidence intervals
will be two-sided, and the significance level is set at 5 %.
Baseline characteristics
All baseline characteristics (see Appendix 1) will be
summarised by randomised group. Summary measures
for the baseline characteristics of each group will be pre-
sented as mean and SD for continuous, approximately
normally distributed variables; medians and interquartile
Fig. 1 Consolidated Standards of Reporting Trials (CONSORT) trial flow diagram
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ranges will be used for non-normally distributed vari-
ables; and frequencies and percentages will be used for
categorical variables. These summaries will be based on
observations only, and the number of missing observa-
tions for each characteristic will be reported.
For all outcomes, a generalised linear model (GLM)
that includes treatment arm, baseline value and centre
as covariates will be fitted. As the primary outcome is
binary, if there are many centres enrolled that recruit
only a small number of participants, a sensitivity analysis
exploring suitable methods to adjust for centre in the
model will be undertaken [12].
Analysis of primary outcome
The proportion of participants with improvement in VA
≥10 letters (yes or no) will be tabulated by treatment
arm and time point. Initially, an unadjusted difference in
proportion at 6 months between treatment arms will be
calculated with 95 % confidence intervals. The adjusted
treatment effect estimate will be obtained by fitting a
GLM with improvement in VA ≥10 letters (yes or no) as
the outcome, and study arm and baseline VA scores as
the covariates. The treatment effect estimate will be re-
ported with a two-sided 95 % confidence interval and
corresponding p value. A GLM with binomial distribu-
tion and logit link function will be used, and the odds
ratio will be reported with 95 % confidence interval.
Sensitivity analyses for primary outcome
As the intervention is a one-off treatment at the time of
randomisation and the two follow-up appointments fol-
low usual clinical care, we anticipate a low percentage of
missing primary outcome data. It is anticipated that
missing data will be missing at random (MAR). A sensi-
tivity analysis of the primary outcome will be undertaken
to assess the impact of participants with missing VA
scores at 6-month follow-up. The number, pattern and
timing of missing data will be examined by treatment
arm along with the reasons for withdrawal or for missing
data. Potential bias due to missing data will be investi-
gated initially by comparing the baseline characteristics
(using descriptive comparisons) between participants
with complete follow-up measurements and those with-
out primary outcome data. A missing indicator variable
(yes or no) will be generated for data at 6 months, and
the relationship between study variables and missingness
will be examined using logistic regression. On the basis
of our exploration of missing data, we will consider
whether our assumption of MAR is reasonable.
Due to the anticipated small number of missing data
and the binary primary outcome, we will initially under-
take an extreme value analysis to examine the impact of
missing data. The sensitivity analysis will consider opti-
mistic and pessimistic scenarios for patients in both
treatment arms. Our missing data analysis will be complete
if we find the results are consistent with the primary ana-
lysis. If the results include a range of values inconsistent
with the primary analysis we will undertake a sensitivity
analysis with more plausible assumptions using multiple
imputation. Datasets will be imputed using the method
described by Carpenter and Kenward [13]. If there is an
unexpectedly large number of participants lost to follow-up
and we consider that the data may be missing not at
random, then we will examine the impact of this using
multiple imputation with a weighting approach described
by Carpenter, Kenward and White [14].
Sub-group analysis
Sub-group analysis will be performed for the primary
outcome to explore the uniformity of the treatment
effects found overall. The following sub-groups will be
examined:
1. Retinal detachment: Attached, traction retinal
detachment and rhegmatogenous retinal detachment
2. Foveal involvement: Yes, no and splitting
3. Presence of PVR: Yes and no
4. Presence of retinal incarceration: Yes and no
5. Lens status at baseline: Clear (phakic), cataract
(phakic), pseudophakic (anterior chamber and
posterior chamber intraocular lens) and aphakic
Each sub-group analysis will be performed by adding
the relevant treatment-by-sub-group interaction term to
the same analytical model used for the primary outcome.
p Values for each interaction term will be presented. No
adjustment for multiple tests will be made, and the
results will be viewed as hypothesis-generating only. The
consistency of estimates will be depicted visually by
means of a forest plot.
Analysis of secondary outcomes
Analysis of secondary outcomes will be undertaken using
a similar approach to that described for the primary
analysis. Secondary outcomes will be summarised and
tabulated by treatment arm and time point. We will esti-
mate and test for a difference between treatment arms for
each endpoint specified in the secondary outcomes listed
above. Initially, an unadjusted difference and 95 % confi-
dence interval will be calculated. A suitable GLM will then
be fitted for each outcome. The logit link and binomial
distribution will be used for binary outcomes, to identify
link and Gaussian distribution for continuous outcomes,
and log-link and Poisson distribution for count outcomes,
which will include an overdispersion parameter if re-
quired,. Centre and baseline values will be included where
appropriate as covariates in the models. The validated
VFQ-25 will be used to score quality-of-life outcomes
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according to manual guidance, and the composite VFQ-25
score will be analysed as a continuous outcome. The CSRI
and the EQ-5D-5L questionnaire will be analysed by the
health economist.
Model assessment
For all methods outlined, goodness of fit will be checked
using standard methods, such as the Hosmer-Lemeshow
test to look at the discrepancy between observed and
predicted values and residual plots to assess model as-
sumptions. We will examine if there are any observations
that have an undue influence on the model by looking at
residual plots, and, where suitable, we will calculate Cook’s
distance statistic. If model assumptions are not deemed to
be valid or the model appears to be misspecified, we will
undertake a sensitivity analysis with an alternative model.
Adherence to allocated treatment and attrition
There is no monitoring of adherence, owing to the in-
tervention and randomisation procedure, which occurs
intraoperatively after the surgeon completes standard
surgical procedures. For those randomised to the inter-
vention arm, the investigational medicinal product is ad-
ministered into the study eye immediately following
randomisation.
Reasons for withdrawal from follow-up assessments will
be summarised. Loss to follow-up over the 6 months is
expected to be minimal, as there are only two data collec-
tion time points, both of which follow standard clinical
care visits. It was assumed that no more than 7 % would
be lost to follow-up, and this has been accounted for in
the sample size of 300. The proportion of participants
missing each of the primary and secondary outcomes will
be summarised by each treatment arm.
Harm data
Information on adverse events will be collected by means
of spontaneous reports from patients and caregivers as
well as clinical observation. No dictionary for coding ad-
verse events will be used, and events will be coded using
terms chosen by the clinical investigators. Adverse events,
adverse reactions, serious adverse events and serious ad-
verse reactions will be tabulated by allocated treatment
arm for both the number of events and the number of
participants with events. Along with the tabulation of the
number of participants with raised IOP by treatment arm,
the mean IOP and SD for each treatment group will be
calculated for all participants by treatment arm. No formal
statistical comparisons will be made.
Conclusions
In this article, we describe the ASCOT trial statistical ana-
lysis plan and outline how data analysis will be performed.
The protocol for the trial is published by Banerjee and
colleagues [15]. We believe that, by making our statistical
analytical plan visible and accessible, transparency regard-
ing decisions made on the analysis of trial data will be
maximised a priori, thus encouraging a balanced, accurate
and complete reporting of results.
Trial status
Recruitment started in December 2014 and is currently
ongoing. We anticipate that the last patient will be
followed in September 2017.
Appendix 1: Baseline characteristics
The following baseline characteristics will be summarised
by treatment arm:
1. Age
2. Sex
3. Ethnicity
4. Current smoker
5. Injury eye (left, right, both)
6. Ocular history condition (glaucoma, previous eye
surgery, macular disease)
7. Cause of study eye injury
8. Previous primary repair
9. Classification of eye injury (rupture, penetrating,
perforating, intraocular foreign body)
10.Extent of eye injury (zone 1, 2 or 3)
11.Presence of relative afferent pupil defect
12.Visual axis corneal scar
13.Uveitis
14.Hyphaema
15.Iris: normal, incomplete or incarcerated
16.Lens: clear, cataract, anterior or posterior chamber
intraocular lens, aphakic intraocular lens
17.Vitreous haemorrhage
18.Endophthalmitis
19.ETDRS (total score or counting fingers/hand
motion/light perception/no light perception)
20.Intraocular pressure
21.Retinal attachment (attached, traction retinal
detachment, rhegmatogenous retinal detachment)
22.Fovea off (yes, no, splitting)
23.Presence of PVR
24.Presence of retinal incarceration
Abbreviations
ASCOT, Adjunctive Steroid Combination in Ocular Trauma; CONSORT,
Consolidated Standards of Reporting Trials; CSRI, Client Service Receipt
Inventory; ETDRS, Early Treatment Diabetic Retinopathy Study, the standard
scale to test visual acuity, which is based on letters of decreasing size on a
chart; GLM, generalised linear model; IOP, intraocular pressure; KCTU, King’s
Clinical Trials Unit; MAR, missing at random; OGT, open globe trauma; PVR,
proliferative vitreoretinopathy; VA, visual acuity; VFQ-25, 25-item Visual
Function Questionnaire
Lo et al. Trials  (2016) 17:383 Page 6 of 7
Acknowledgements
The authors thank the valuable contributions to the statistical analysis plan
made by the study team and committee members: Trial Steering Committee
(David Broadway, Nick Freemantle, Tim Jackson, Noemi Lois), Data
Monitoring Committee (Colin Dayan, John Ellis, Paul Silcocks), King’s Clinical
Trial Unit team (Caroline Murphy, Joanna Kelly and Beverley White-Alao) and
Trial Manager Elizabeth Robertson. The ASCOT trial is funded by a project
grant from the National Institute for Health Research Health Technology
Assessment (HTA) programme (HTA 12/35/64).
Authors’ contributions
JWL, RP and VRC drafted and finalised the statistical analysis plan. CB and
VRC were the statisticians on the grant application.
DC is the chief investigator. PB the co-investigator. VC, DC and PB designed
the study. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Author details
1Department of Primary Care and Public Health Sciences, King’s College
London, 4th Floor Addison House, Guy’s Campus, London SE1 1UL, UK.
2Moorfields Eye Hospital NHS Foundation Trust, City Road, London EC1V
2PD, UK. 3National Institute for Health Research (NIHR) Biomedical Research
Centre for Ophthalmology at Moorfields Eye Hospital NHS Foundation Trust
and UCL Institute of Ophthalmology, 162 City Road, London EC1V 2PD, UK.
4National Institute for Health Research (NIHR) Clinical Research Facility at
Moorfields Eye Hospital, London, UK. 5National Institute for Health Research
(NIHR) Biomedical Research Centre at Guy’s and St. Thomas’ NHS Foundation
Trust and King’s College London, London, UK. 6King’s Clinical Trials Unit,
Institute of Psychiatry, King’s College London, London, UK. 7Imperial Clinical
Trials Unit, School of Public Health, Imperial College London, Stadium House,
68 Wood Lane, London W12 7RH, UK.
Received: 29 January 2016 Accepted: 21 June 2016
References
1. Esmaeli B, Elner SG, Schork MA, Elner VM. Visual outcome and ocular
survival after penetrating trauma: a clinicopathologic study. Ophthalmology.
1995;102(3):393–400.
2. Negrel AD, Thylefors B. The global impact of eye injuries. Ophthalmic
Epidemiol. 1998;5(3):143–69.
3. Cardillo JA, Stout JT, LaBree L, Azen SP, Omphroy L, Cui LZ, et al. Post-
traumatic proliferative vitreoretinopathy: the epidemiologic profile, onset,
risk factors, and visual outcome. Ophthalmology. 1997;104(7):1166–73.
4. Spiegel D, Nasemann J, Nawrocki J, Gabel VP. Severe ocular trauma
managed with primary pars plana vitrectomy and silicone oil. Retina. 1997;
17(4):275–85.
5. Framme C, Roider J. Epidemiology of open globe injuries [in German]. Klin
Monbl Augenheilkd. 1999;215(5):287–93.
6. Mittra RA, Mieler WF. Controversies in the management of open-globe injuries
involving the posterior segment. Surv Ophthalmol. 1999;44(3):215–25.
7. Charteris DG, Sethi CS, Lewis GP, Fisher SK. Proliferative
vitreoretinopathy—developments in adjunctive treatment and retinal
pathology. Eye. 2002;16(4):369–74.
8. Patel NN, Bunce C, Asaria RH, Charteris DG. Resources involved in managing
retinal detachment complicated by proliferative vitreoretinopathy. Retina.
2004;24(6):883–7.
9. Tano Y, Chandler D, Machemer R. Treatment of intraocular proliferation with
intravitreal injection of triamcinolone acetonide. Am J Ophthalmol. 1980;
90(6):810–6.
10. Albini TA, Abd-El-Barr MM, Carvounis PE, Iyer MN, Lakhanpal RR, Pennesi ME,
et al. Long-term retinal toxicity of intravitreal commercially available
preserved triamcinolone acetonide (Kenalog) in rabbit eyes. Invest
Ophthalmol Vis Sci. 2007;48(1):390–5.
11. Kaiser PK. Prospective evaluation of visual acuity assessment: a comparison
of Snellen versus ETDRS charts in clinical practice (an AOS thesis). Trans Am
Ophthalmol Soc. 2009;107:311–24.
12. Kahan BC. Accounting for centre-effects in multicentre trials with binary
outcome – when, why, and how? BMC Med Res Methodol. 2014;14:20.
13. Carpenter JR, Kenward MG. Missing data in randomised controlled
trials—a practical guide. Birmingham, UK: National Health Service
(NHS) Coordinating Centre for Research Methodology; 21 Nov 2007.
http://missingdata.lshtm.ac.uk/downloads/rm04_jh17_mk.pdf.
Accessed 25 Jan 2016.
14. Carpenter JR, Kenward MG, White IR. Sensitivity analysis after multiple
imputation under missing at random: a weighting approach. Stat Methods
Med Res. 2007;6(3):259–75.
15. Banerjee PJ, Cornelius VR, Phillips R, Lo JW, Bunce C, Kelly J, et al. Adjunctive
intraocular and peri-ocular steroid (triamcinolone acetonide) versus
standard treatment in eyes undergoing vitreoretinal surgery for open globe
trauma (ASCOT): study protocol for a phase III, multi-centre, double-masked
randomised controlled trial. Trials. 2016;17(1):339.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Lo et al. Trials  (2016) 17:383 Page 7 of 7
